Group 1: BeiGene Overview - BeiGene, Ltd. (BGNE) shares increased by 5.3% to close at $246.04, with a notable trading volume compared to normal sessions, and a total gain of 22% over the past four weeks [1] - The rise in stock price is linked to positive investor sentiment regarding BeiGene's marketed drug portfolio, which includes three approved medicines: Brukinsa, Tevimbra, and Partruvix, along with a robust pipeline of investigational candidates [1] - The company is projected to report a quarterly loss of $0.94 per share, reflecting a year-over-year decline of 146.8%, while revenues are expected to reach $976.82 million, marking a 25% increase from the previous year [1] Group 2: Earnings and Stock Performance - Trends in earnings estimate revisions are correlated with near-term stock price movements, and BeiGene's consensus EPS estimate has remained unchanged over the last 30 days [2] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the need to monitor BGNE for potential future strength [2] - BeiGene holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [2] Group 3: Industry Comparison - BeiGene is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Foghorn Therapeutics Inc. (FHTX), which saw a 4.7% increase to $7.83 but has returned -7.4% over the past month [2] - Foghorn Therapeutics has a consensus EPS estimate that has changed by +2.5% to -$0.42, representing a 23.5% decline from the previous year [3] - Foghorn Therapeutics also holds a Zacks Rank of 3 (Hold), similar to BeiGene [3]

根据 1934 年证券交易法 第 13 或 15（d）条规定提交的 临时报告 报告日期（所报告最早事件之日期）：2024 年 9 月 30 日 百济神州有限公司 美国证券交易委员会 华盛顿特区 20549 8-K 表格 _____________________ BEIGENE, LTD. 开曼群岛 001-37686 98-1209416 （注册地所在州或其他司法管辖区） （委员会档案编号） （国税局雇主识别号） c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 Cayman Islands （主要办事处地址）（邮政编码） +1 (345) 949 4123 （注册人电话号码，包括区号） 不适用 （注册人章程中列明的注册人准确名称） （如自上一份报告起有改动，则为公司曾用名或原地址） 若 8-K 表格的呈递旨在同时满足下列任何条例项下的注册人报告义务，请勾选相应方格： ☐ 根据证券法第 425 条发出书面通讯 (17 CFR 230.425) ☐ 根据交易法 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事 ...

BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 董事名單及其角色與職能 百濟神州有限公司（「本公司」）董事會（「董事會」）成員載於下文。 執行董事 歐雷強先生 （主席兼首席執行官） 非執行董事 董事會有五個董事會委員會。下表提供本公司每位董事所任職於這些委員會的成 員資料。 | | | | | | 商業及醫學 | | --- | --- | --- | --- | --- | --- | | | | | 提名及企業 | 科學諮詢 | 事務諮詢 | | | 審計委員會 | 薪酬委員會 | 管治委員會 | 委員會 | 委員會 | | 歐雷強先生 | | | | | | | 王曉東博士 | | | | CC | | | Olivier Brandicourt博士 | M | | | | M | | Margaret Han Dugan博士 | | C | | M | M | | Donald W. Glazer先生 | | | C | | | | Michael Goller先生 | | | M | M | | | Anthony C. Hooper先生 | ...

A 股代码：688235 A 股简称：百济神州 公告编号：2024-023 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于委任独立非执行董事及董事会审计委员会成员 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经百济神州有限公司（以下简称"公司"）董事会（以下简称"董事会"） 审议，Shalini Sharp 女士（以下简称"Sharp 女士"）被任命为董事会独立非执 行董事，自 2024 年 9 月 27 日起生效。现将有关情况公告如下： 经公司董事会审议通过，公司董事会成员从 11 位增加至 12 位，并任命 Sharp 女士填补因董事会成员增加而出现的成员空缺，自 2024 年 9 月 27 日起生 效。Sharp 女士将担任公司独立非执行董事和第 III 类董事，任期直至 2025 年公 司年度股东大会以及其继任人获正式选举及符合资格为止，但其可提前辞任或 被罢免。 同时，Sharp 女士被任命为董事会审计委员会（以下简称"审计委员会"） 成员。公司董事会审计委员会由 ...

2024 中期報告 Cancer has no borders. Neither do we. 目錄 | 公司資料 | 2 | | --- | --- | | 前瞻性陳述 | 4 | | 管理層討論及分析 | 7 | | 其他資料 | 26 | | 未經審核中期簡明綜合經營表 | 76 | | 未經審核中期簡明綜合全面虧損表 | 77 | | 未經審核中期簡明綜合資產負債表 | 78 | | 未經審核中期簡明綜合股東權益報表 | 80 | | 未經審核中期簡明綜合現金流量表 | 81 | | 未經審核中期簡明綜合財務報表附註 | 83 | | 釋義 | 120 | | 技術詞彙 | 124 | 1 百濟神州有限公司 • 2024 中期報告 公司資料 董事會 執行董事 歐雷強先生 （主席兼首席執行官） 非執行董事 王曉東博士 獨立非執行董事 Olivier Brandicourt博士 （附註1） Margaret Han Dugan博士 Donald W. Glazer先生 Michael Goller先生 Anthony C. Hooper先生 Ranjeev Krishana先生 Alessandro Ri ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the first half of 2024, representing a 25% year-over-year growth[6]. - Total revenue for Q2 2024 reached $929 million, a year-on-year increase of 56%[11]. - Total revenue for the six months ended June 30, 2024, was $1,680,818 thousand, a 61.1% increase from $1,043,062 thousand in the same period of 2023[18]. - Product revenue reached $1,668,064 thousand, up 73.0% from $964,036 thousand in the prior year, driven by increased sales of proprietary products Baiyueze® and Baizean®[20]. - The company reported a net loss of approximately $371.6 million, compared to a net loss of approximately $729.6 million for the same period in 2023[36]. - Operating loss decreased by 46.6% to $368.5 million for the six months ending June 30, 2024, compared to a loss of $690 million in the same period in 2023[17]. - The gross profit for the six months ended June 30, 2024, rose to $1.405 billion, compared to $786.3 million in the same period last year, with a gross margin of 84.2%[22]. Research and Development - Investment in R&D has increased by 20%, with a focus on developing new therapies and technologies to enhance treatment options[6]. - Research and development expenses increased by 10.1% to $915.1 million for the six months ending June 30, 2024[17]. - Key projects for BCL2 inhibitor sonrotoclax and BTK degrader BGB-16673 are progressing steadily[11]. - Over 15 innovative molecules in the pipeline for solid tumors, including ADCs and targeted therapies for lung, breast, and gastrointestinal cancers[11]. - The company has established a global development and medical affairs team of over 3,000 colleagues across five continents, enabling independent clinical trials[13]. - The company aims to provide impactful, accessible, and affordable medications to more patients globally[13]. Market Expansion and Strategy - The company is planning to enter new markets in Europe and Asia, aiming for a 10% market share in these regions by the end of 2025[6]. - A strategic acquisition of a biotech firm was announced, expected to enhance the company's product pipeline and accelerate growth[6]. - The company has successfully launched two new products in Q2 2024, contributing to a 15% increase in market penetration[6]. - Future guidance includes a commitment to achieving profitability by Q4 2025, with a focus on operational efficiency and cost reduction[6]. - The company plans to leverage its pipeline, including sonrotoclax and BTK-CDAC, to strengthen its position in CLL treatment and expand into other B-cell malignancies[15]. Financial Position and Cash Flow - The company aims to maintain a strong cash position, with cash reserves of $200 million, ensuring sufficient liquidity for future investments[6]. - The company has a strong financial position with approximately $2.6 billion in cash and cash equivalents as of June 30, 2024[16]. - Cash used in operating activities was $404.2 million for the six months ended June 30, 2024, down from $857.7 million for the same period in 2023[38]. - Cash and cash equivalents decreased to $2,592,655 thousand as of June 30, 2024, down from $3,171,800 thousand, a decline of 18.2%[144]. - The company expects to have sufficient cash and cash equivalents to meet operational and capital expenditure needs for at least 12 months following the date of the financial statements[36]. Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and transparency in its operations[120]. - The audit committee consists of three independent non-executive directors, ensuring oversight of financial reporting integrity[122]. - The company has maintained compliance with corporate governance codes and regulations throughout the reporting period[123]. - The chairman and CEO roles are currently held by the same individual, which the board believes facilitates effective execution of strategic initiatives[121]. Stock Options and Employee Compensation - The company has granted stock options to various executives, with the maximum potential shares for Brandicourt being 61,945 upon exercise[60]. - The total compensation cost incurred by the company for the six months ended June 30, 2024, was $891.8 million, compared to $753.0 million for the same period in 2023, reflecting an increase in labor costs[53]. - The company has a total of 34,151 stock options that remain unexercised for 2024[88]. - The stock options granted have a vesting schedule where 25% can be exercised after one year, with the remaining 75% vesting monthly over three years[98]. Collaborations and Partnerships - The company has established collaborations with world-leading biopharmaceutical companies to develop and commercialize innovative drugs[150]. - The company’s collaboration revenue for the six months ended June 30, 2024, was primarily derived from agreements with Novartis[162]. - The company has regained full global rights for the development, production, and commercialization of Tislelizumab after terminating the collaboration with Novartis in September 2023[164]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 30% for the full year 2024, driven by new product launches and market expansion[6]. - The company plans to continue expanding its market presence and product offerings in the upcoming quarters[90]. - Future guidance suggests a focus on new product development and potential acquisitions to enhance market position[90].

A 股代码：688235 A 股简称：百济神州 公告编号：2024-022 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于 2024 年第一次临时股东大会（股东特别大会） 股权登记日的公告 本公司董事会及全体董事保证公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性依法承担法律责任。 重要内容提示： 1、百济神州有限公司（以下简称"公司"）2024 年第一次临 时股东大会（股东特别大会）（以下简称"2024 年股东特别大 会"）的股权登记日为 2024 年 10 月 8 日。 2、与 2024 年股东特别大会相关的其他后续事项，包括但不 限于会议日期、会议地点、审议事项、投票注意事项、会议出席 对象、会议登记方法等，敬请关注公司后续披露的关于 2024 年 股东特别大会通知及相关公告。 （4）公司美国存托股份持有人：记录日期为 2024 年 10 月 8 日（星期二）上午六时（美国纽约时间）。 二、与 2024 年股东特别大会相关的后续事项 一、2024 年股东特别大会的股权登记日 公司系根据《开曼群岛公司法》设立且股票在上海证券交 ...

中国国际金融股份有限公司、高盛（中国）证券有限责任公司 关于百济神州有限公司 2024 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）、 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》、《科创板上 市公司持续监管办法（试行）》等有关法律、法规的规定，中国国际金融股份有 限公司与高盛（中国）证券有限责任公司（以下与中国国际金融股份有限公司合 称"联席保荐机构"）作为百济神州有限公司（以下简称"百济神州"或"公司"） 持续督导工作的联席保荐机构，负责百济神州上市后的持续督导工作，并出具 2024 年半年度持续督导跟踪报告，本持续督导期间为 2024 年 1 月 1 日至 2024 年 6 月 30 日。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制 | 联席保荐机构已建立健全并有效执行 | | | 度，并针对具体的持续督导工作制定相 | 了持续督导制度，并制定了相应的工作 | | | 应的工作计划 ...

FF305 呈交日期： 2024年9月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股 ...